People with Type 2 Diabetes Achieve Superior Outcomes with Insulin Pumps vs. Multiple Daily InjectionsContinue reading
Author Archive: AZBio
Ultherapy® Décolletage Treatment Now FDA-Cleared
First Non-invasive Procedure Specifically Indicated by the FDA to Improve Lines and Wrinkles on the DécolletéContinue reading
Check out the Program for AdvaMed 2014
AZBio Members Save 20% with Discount Code AZBIO20
Early Bird Discounts End July 31st. Register Today
AdvaMed 2014 brings more than 1,000 companies together in North America’s leading MedTech Conference. The AdvaMed 2014 Program Preview is now available with the latest details about program panels, business development, networking opportunities and special programming.The Program Preview also introduces a few of our plenary speakers, including Former Secretary of State Hillary Rodham Clinton, FDA Commissioner Margaret A. Hamburg, Mayor Rahm Emanuel and more!
Download the Program Preview to get a glimpse of what lies ahead for AdvaMed 2014!
For More Information:
AdvaMed Medtech Conference
Tel: +1.202.434.7213 | Fax: 1.800.442.2318 | info@medtechconference.org
© Copyright 2014 AdvaMed 2014
Opportunity Alert: Director of Genomics Research at Phoenix Children’s Hospital
Position Title: Dir, Genomics Research
For more information or to apply for this position, click here.
Position Details
| Department: Molecular Medicine | Posting #: 44371 |
| Category: Any | Date Posted: 6/19/2014 |
| Schedule: Mon – Fri; Days | Employee Type: Full Time |
| Location: Phoenix | |
Position Summary
The Institutes of Molecular Medicine Genomics Research Director leads the Sequencing group, which provides established services to the research community at Phoenix Children’s Institute, affiliated institutions as well as other academic and non-academic groups. A main goal is to improve existing and evaluate new technologies with a focus on clinical translation. The Director interacts closely with the Director of Clinical Sequencing to evaluate novel technologies, provide technical expertise on existing platforms and help PCH clinical investigators formulate/design research questions in genomics in the field of cancer and inherited disease. Therefore, the research director has abundant opportunity for publishing high quality research data. The director is also responsible for growing and managing the quality of the variant database within the Genomics Core and for stimulating and growing genomics research within the Phoenix Children’s Research Institute.
For more information or to apply for this position, click here.
Independence, Independents, and the Importance of Your Vote
Each July 4th we celebrate our independence as a nation and as a free people. The freedom and the opportunity to elect our leaders and representatives is as important today as it was in 1776.
Amgen Receives FDA Breakthrough Therapy Designation For Investigational BiTE® Antibody Blinatumomab In Acute Lymphoblastic Leukemia
Breakthrough Designation Reinforces Significant Unmet Need in the Treatment of This Highly Aggressive CancerContinue reading
Non-invasive advanced image analysis could lead to better patient care
Lung cancer patients could especially benefit from new ‘QTA’ techniqueContinue reading
OPPORTUNITY ALERT: Clinical Research Director at Regenesis Biomedical
Regenesis currently has a Director of Clinical Research position available for interested professionals.
BIO 2014 Recap – New Connections, New Data, New Opportunities for Arizona’s Bioindustry
The 2014 BIO International Convention, where the global biotech community meets, connecting the people, companies and innovations that help to fulfill the promise of biotechnology through healing, fueling, and feeding the world, concluded today at the San Diego Convention Center with a record number of partnering meetings. Hosted by the Biotechnology Industry Organization (BIO), the event drew 15,667 industry leaders, including nearly 2,500 CEO’s, from 50 states and 70 countries.Continue reading
Regenesis Biomedical Releases Educational Video on Provant Methodof Action
Provant Therapy Mechanism of Action Video Animation Now Available
Life science laboratory research shows Provant treats pain two ways
Scottsdale, Arizona, June 27, 2014 — Regenesis Biomedical Inc., today announced the release of an animation on the Provant Therapy System’s mechanism of action. This video shows how Provant treats pain two ways: anti-nociceptive analgesia, and anti-inflammatory.
Pain management and the treatment of inflammation are important considerations following operative procedures. Persistent pain may lead to reduced physical function and sense of well-being, increased consumption of opioid analgesics, and expensive, invasive ancillary procedures (including hospital readmissions, repeat surgeries, extended physical therapy, lab tests, radiology, epidural injections, and implantation of spinal cord stimulators and intrathecal drug pumps).
“Post-op pain is often undermanaged, and narcotic use continues to rise,” said Scott Brooks, President and Chief Executive Officer of Regenesis Biomedical. “Regenesis’ life science research further validates the pain relief effect seen in Provant patients. As an alternative treatment, Provant may allow patients to avoid expensive procedures, reduce opioid consumption, and avoid opioid negative side effects.”
The video may be viewed at http://www.regenesisbio.com/our-videos.php
About Regenesis Biomedical
Regenesis Biomedical, Inc. is a privately held medical technology company focused on the research, design, manufacture, and sale of energy-based medical products and services that alleviate pain, restore health, and improve quality of life. Regenesis developed, patented, and now markets the Provant Therapy System. Our customers include health care facilities and providers that serve patients treated in acute care hospitals, long-term care, outpatient clinics, and home care.
About the Provant®
Therapy System Provant uses pulsed electromagnetic energy to facilitate reduction of the pain and edema associated with post-operative, superficial soft tissues. Provant relieves pain two ways: through anti-nociceptive analgesia by inducing endogenous opioids, and by regulating inflammatory mediators.
Contact: Regenesis Biomedical, Inc.
Scott Robey, Vice President Marketing
www.regenesisbio.com
480-970-4970 phone
SOURCE: Regenesis Biomedical Inc.